RadNet, Inc. filings document material-event disclosures for operating results, financial condition, governance, capital structure, and corporate actions tied to its diagnostic imaging and digital health businesses. Recent Form 8-K reports furnish quarterly results press releases and exhibits, including segment information for Imaging Centers and Digital Health.
The company’s proxy materials address board matters, executive compensation, and shareholder voting items. Other filings include leadership and compensatory-arrangement disclosures, prospectus supplements under automatic shelf registration statements for common stock resale registrations, and acquisition-related share issuance matters associated with RadNet’s health informatics expansion.
RadNet, Inc. reported that President and CEO Howard G. Berger received a grant of 124,001 shares of Common Stock on March 3, 2026, labeled as a grant, award, or other acquisition with a price of $0.0000 per share. After this award, he directly held 472,413 shares of Common Stock.
The filing also notes an indirect holding of 20,000 shares of Common Stock held "By Spouse", reflected as indirect ownership, without a specified transaction amount on that date.
RadNet, Inc. reported that executive Michael N. Murdock, EVP, Mergers and Acquisitions, received a grant, award, or other acquisition of 6,613 shares of RadNet common stock on March 3, 2026 at a stated price of $0.0000 per share. After this award, he directly owns 46,697 common shares.
RadNet, Inc. reported that executive Alma Gregory Sorensen, who serves as EVP and Chief Science Officer, acquired a grant or award of 16,533 shares of RadNet common stock on March 3, 2026. The transaction was recorded at a price of $0.0000 per share, indicating it was an equity award rather than an open-market purchase.
After this grant, Sorensen directly held a total of 1,181,878 shares of RadNet common stock. The filing classifies the transaction as a direct, non-derivative acquisition.
RadNet, Inc. provides outpatient diagnostic imaging services across the U.S., with 418 centers as of December 31, 2025, making it a large national operator by locations and imaging revenue. The company offers MRI, CT, PET, mammography, ultrasound, X-ray, nuclear medicine and fluoroscopy, mostly through multi‑modality centers that serve patients, referring physicians and payors in nine states.
RadNet also operates a growing Digital Health segment, led by its DeepHealth subsidiary, delivering AI‑enabled radiology software, RIS/PACS and workflow tools. This segment includes acquisitions such as Aidence, Quantib, ICAD and CIMAR, serves over 2,000 customers, and holds 22 FDA clearances and 15 CE marks.
Strategy centers on expanding center networks and joint ventures with hospitals, scaling AI and cloud‑based platforms, improving operating efficiency, and deepening relationships with commercial, capitated and government payors. Key risks include reimbursement pressure from Medicare and managed care, regulatory scrutiny, inflation-driven labor and equipment costs, competition from hospitals and independent operators, and operational disruption from economic conditions, natural disasters and public health events.
RadNet, Inc. provides outpatient diagnostic imaging services across the U.S., with 418 centers as of December 31, 2025, making it a large national operator by locations and imaging revenue. The company offers MRI, CT, PET, mammography, ultrasound, X-ray, nuclear medicine and fluoroscopy, mostly through multi‑modality centers that serve patients, referring physicians and payors in nine states.
RadNet also operates a growing Digital Health segment, led by its DeepHealth subsidiary, delivering AI‑enabled radiology software, RIS/PACS and workflow tools. This segment includes acquisitions such as Aidence, Quantib, ICAD and CIMAR, serves over 2,000 customers, and holds 22 FDA clearances and 15 CE marks.
Strategy centers on expanding center networks and joint ventures with hospitals, scaling AI and cloud‑based platforms, improving operating efficiency, and deepening relationships with commercial, capitated and government payors. Key risks include reimbursement pressure from Medicare and managed care, regulatory scrutiny, inflation-driven labor and equipment costs, competition from hospitals and independent operators, and operational disruption from economic conditions, natural disasters and public health events.
RadNet, Inc. provides outpatient diagnostic imaging services across the U.S., with 418 centers as of December 31, 2025, making it a large national operator by locations and imaging revenue. The company offers MRI, CT, PET, mammography, ultrasound, X-ray, nuclear medicine and fluoroscopy, mostly through multi‑modality centers that serve patients, referring physicians and payors in nine states.
RadNet also operates a growing Digital Health segment, led by its DeepHealth subsidiary, delivering AI‑enabled radiology software, RIS/PACS and workflow tools. This segment includes acquisitions such as Aidence, Quantib, ICAD and CIMAR, serves over 2,000 customers, and holds 22 FDA clearances and 15 CE marks.
Strategy centers on expanding center networks and joint ventures with hospitals, scaling AI and cloud‑based platforms, improving operating efficiency, and deepening relationships with commercial, capitated and government payors. Key risks include reimbursement pressure from Medicare and managed care, regulatory scrutiny, inflation-driven labor and equipment costs, competition from hospitals and independent operators, and operational disruption from economic conditions, natural disasters and public health events.
RadNet, Inc. reports record 2025 results and raises its outlook for 2026. For the fourth quarter of 2025, revenue rose 14.8% year over year to $547.7 million and Adjusted EBITDA(1) grew 16.9% to $87.7 million, driven by strong volume growth in advanced imaging modalities and efficiency gains in imaging centers.
For full-year 2025, revenue increased 11.5% to $2,040.2 million and Adjusted EBITDA(1) reached $300.2 million, though RadNet recorded a net loss attributable to common stockholders of $18.7 million, or $(0.25) per diluted share, versus net income of $0.04 per share in 2024.
The Digital Health segment delivered 2025 revenue of $92.7 million, up 41.1%, with Annual Recurring Revenue(4) of $75.4 million at December 31, 2025. Management highlights accelerating adoption of AI-powered workflow and clinical tools, aided by acquisitions including Gleamer, and expects Digital Health ARR to approach or exceed $140 million by the end of 2026.
RadNet’s 2026 guidance calls for Imaging Center segment revenue of $2.325–$2.375 billion, Adjusted EBITDA(1) of $335–$348 million and free cash flow(2) of $105–$115 million. Digital Health guidance anticipates 45%–55% revenue growth from 2025 levels, supported by new AI products, additional FDA clearances and ongoing infrastructure investment.
RadNet, Inc. reports record 2025 results and raises its outlook for 2026. For the fourth quarter of 2025, revenue rose 14.8% year over year to $547.7 million and Adjusted EBITDA(1) grew 16.9% to $87.7 million, driven by strong volume growth in advanced imaging modalities and efficiency gains in imaging centers.
For full-year 2025, revenue increased 11.5% to $2,040.2 million and Adjusted EBITDA(1) reached $300.2 million, though RadNet recorded a net loss attributable to common stockholders of $18.7 million, or $(0.25) per diluted share, versus net income of $0.04 per share in 2024.
The Digital Health segment delivered 2025 revenue of $92.7 million, up 41.1%, with Annual Recurring Revenue(4) of $75.4 million at December 31, 2025. Management highlights accelerating adoption of AI-powered workflow and clinical tools, aided by acquisitions including Gleamer, and expects Digital Health ARR to approach or exceed $140 million by the end of 2026.
RadNet’s 2026 guidance calls for Imaging Center segment revenue of $2.325–$2.375 billion, Adjusted EBITDA(1) of $335–$348 million and free cash flow(2) of $105–$115 million. Digital Health guidance anticipates 45%–55% revenue growth from 2025 levels, supported by new AI products, additional FDA clearances and ongoing infrastructure investment.
RadNet, Inc. reports record 2025 results and raises its outlook for 2026. For the fourth quarter of 2025, revenue rose 14.8% year over year to $547.7 million and Adjusted EBITDA(1) grew 16.9% to $87.7 million, driven by strong volume growth in advanced imaging modalities and efficiency gains in imaging centers.
For full-year 2025, revenue increased 11.5% to $2,040.2 million and Adjusted EBITDA(1) reached $300.2 million, though RadNet recorded a net loss attributable to common stockholders of $18.7 million, or $(0.25) per diluted share, versus net income of $0.04 per share in 2024.
The Digital Health segment delivered 2025 revenue of $92.7 million, up 41.1%, with Annual Recurring Revenue(4) of $75.4 million at December 31, 2025. Management highlights accelerating adoption of AI-powered workflow and clinical tools, aided by acquisitions including Gleamer, and expects Digital Health ARR to approach or exceed $140 million by the end of 2026.
RadNet’s 2026 guidance calls for Imaging Center segment revenue of $2.325–$2.375 billion, Adjusted EBITDA(1) of $335–$348 million and free cash flow(2) of $105–$115 million. Digital Health guidance anticipates 45%–55% revenue growth from 2025 levels, supported by new AI products, additional FDA clearances and ongoing infrastructure investment.
RadNet, Inc. has completed an all-cash acquisition of Paris-based radiology AI company Gleamer SAS for up to €230 million, including about €215 million paid at closing and a contingent €15 million tied to future milestones.
Gleamer, with more than 130 professionals and over 700 customer contracts across 44 countries, will be integrated into RadNet’s DeepHealth digital health segment. Combining Gleamer’s multimodality, FDA-cleared and CE-marked AI tools with DeepHealth’s existing portfolio is described as making DeepHealth the largest provider of radiology clinical AI solutions worldwide.
The companies highlight benefits such as automated exam prioritization, draft reporting, and workflow automation across X-ray, CT, MR, mammography and ultrasound. DeepHealth and Gleamer together anticipate annual recurring revenue approaching or exceeding $140 million by the end of 2026, backed by a broad installed base and high recurring-revenue profile.
RadNet, Inc. has completed an all-cash acquisition of Paris-based radiology AI company Gleamer SAS for up to €230 million, including about €215 million paid at closing and a contingent €15 million tied to future milestones.
Gleamer, with more than 130 professionals and over 700 customer contracts across 44 countries, will be integrated into RadNet’s DeepHealth digital health segment. Combining Gleamer’s multimodality, FDA-cleared and CE-marked AI tools with DeepHealth’s existing portfolio is described as making DeepHealth the largest provider of radiology clinical AI solutions worldwide.
The companies highlight benefits such as automated exam prioritization, draft reporting, and workflow automation across X-ray, CT, MR, mammography and ultrasound. DeepHealth and Gleamer together anticipate annual recurring revenue approaching or exceeding $140 million by the end of 2026, backed by a broad installed base and high recurring-revenue profile.
RadNet, Inc. has completed an all-cash acquisition of Paris-based radiology AI company Gleamer SAS for up to €230 million, including about €215 million paid at closing and a contingent €15 million tied to future milestones.
Gleamer, with more than 130 professionals and over 700 customer contracts across 44 countries, will be integrated into RadNet’s DeepHealth digital health segment. Combining Gleamer’s multimodality, FDA-cleared and CE-marked AI tools with DeepHealth’s existing portfolio is described as making DeepHealth the largest provider of radiology clinical AI solutions worldwide.
The companies highlight benefits such as automated exam prioritization, draft reporting, and workflow automation across X-ray, CT, MR, mammography and ultrasound. DeepHealth and Gleamer together anticipate annual recurring revenue approaching or exceeding $140 million by the end of 2026, backed by a broad installed base and high recurring-revenue profile.
RTW Investments, LP and Roderick Wong, M.D. report beneficial ownership of 3,938,500 shares of RadNet, Inc. common stock, representing 5.1% of the company’s outstanding shares. This stake relates to RadNet’s common stock with a $0.0001 par value.
The ownership is held through certain RTW-managed funds, with RTW Investments acting as investment adviser and Dr. Wong as Managing Partner and Chief Investment Officer. Voting and dispositive power over all 3,938,500 shares is shared. The investors state the shares were acquired and are held in the ordinary course of business, not to change or influence control of RadNet.
RadNet, Inc. has registered for resale up to 190,924 shares of its common stock through a prospectus supplement to its automatic shelf registration statement. These shares will be issued to the Cimar Sellers or their designees as the non-cash portion of the consideration for RadNet’s acquisition of all shares in Cimar (UK) Limited, completed on November 10, 2025. The acquisition was executed under a Share Purchase Agreement between the Cimar Sellers and DH AI International Holdings, B.V., RadNet’s wholly owned Dutch subsidiary. RadNet also filed a legal opinion from Reed Smith LLP on the validity of the registered securities as an exhibit.
RadNet, Inc. is registering the resale of up to 190,924 shares of common stock issued to the former owners of Cimar (UK) Limited as the non-cash portion of the purchase price under a November 10, 2025 share purchase agreement.
The Cimar Sellers received stock equal to half of approximately £20.1 million due at closing, and this filing satisfies their registration rights so they can sell those shares over time. RadNet will not receive any proceeds from these sales, though it is paying the registration and related expenses. The selling stockholders may dispose of shares through various public or private sale methods at market, fixed, or negotiated prices.
RadNet, Inc. expanded its executive leadership team and adjusted compensation for key executives. The company promoted Stephen Forthuber to President and Chief Executive Officer, Eastern Operations, and Norman Hames to President and Chief Executive Officer, Western Operations. Mital Patel was promoted to Executive Vice President and Chief Operating Officer.
In connection with these changes and routine compensation updates effective January 1, 2026, the Compensation Committee approved new annual base salaries of $950,000 for Mr. Forthuber, $950,000 for Mr. Hames, and $925,000 for Mr. Patel. The committee also set annual base salaries of $850,000 for Executive Vice President and Chief Financial Officer Mark Stolper and $850,000 for Cornelis Wesdorp, President and Chief Executive Officer, Digital Health. All other terms of their existing employment agreements remain unchanged.